GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Hydroxyurea scored tablets - SIKLOS

Read renal action and limits
Local official-label summarySource retrieved 2026-09-07See the evidence for this drug3 sources available - open source summaries, references and comparisons

SIKLOS / Hydroxyurea

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

2 additional source qualifications - review before use
The same 50% renal reduction starts from different adult and pediatric doses

SIKLOS provides separate pediatric and adult starting doses. The DROXIA extract is adult capsule guidance. Applying the adult starting amount to a child would change the regimen even if the percentage reduction were correct.

Before applying: Use the exact age/product starting dose, prescribed weight method, measured CrCl instruction and hematology monitoring plan. Related hydroxyurea products remain separate.

Siklos - product and source limitations

Verify the age-specific initial dose, tablet strength and hematologic monitoring.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: The same 50% renal reduction starts from different adult and pediatric doses; Siklos - product and source limitations

Official source

Siklos - labeled renal guidance

Renal action and limits

Hydroxyurea (Siklos), oral tablets for sickle cell disease
Measured creatinine clearance, mL/min

Action or finding
Halve the usual Siklos dose when CrCl is below 60 mL/min or ESRD is present. Give the dose after hemodialysis on treatment days.
Limits and monitoring
Verify the age-specific initial dose, tablet strength and hematologic monitoring.
Before use
Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 13, posted Jan 08, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source Siklos | GlobalRPh RX passage All evidence
Product / population
Hydroxyurea (Siklos), oral tablets for sickle cell disease
Renal measure
Measured creatinine clearance, mL/min
Source revision
DailyMed SPL version 13, posted Jan 08, 2026
Retrieved
2026-11-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Renal guidance: 2.2 Dose Modifications for Renal Impairment / 8.6 Renal Impairment

Halve the usual Siklos dose when CrCl is below 60 mL/min or ESRD is present. Give the dose after hemodialysis on treatment days. Verify the age-specific initial dose, tablet strength and hematologic monitoring.

Source revision: DailyMed SPL version 13, posted Jan 08, 2026 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76957c0d-0f98-4376-bb06-eee651adc09d

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Siklos - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 13, posted Jan 08, 2026

Renal measure: Measured creatinine clearance, mL/min

Read this dated source finding
Rxlist

Siklos - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Official product label

Hydroxyurea scored tablets - SIKLOS

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

SIKLOS hydroxyurea 100-mg and 1000-mg scored tablets; sickle cell anemia, age >=2 years

Renal method: CrCl, mL/min, obtained using a 24-hour urine collection
Retrieved: 2026-09-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Siklos - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Hydroxyurea (Siklos), oral tablets for sickle cell disease

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Siklos - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

population and formulation

The same 50% renal reduction starts from different adult and pediatric doses

SIKLOS provides separate pediatric and adult starting doses. The DROXIA extract is adult capsule guidance. Applying the adult starting amount to a child would change the regimen even if the percentage reduction were correct.

How to use this: Use the exact age/product starting dose, prescribed weight method, measured CrCl instruction and hematology monitoring plan. Related hydroxyurea products remain separate.

Hydroxyurea scored tablets - SIKLOSHydroxyurea capsules for sickle cell anemia - DROXIAHydroxyurea capsules (Hydrea, oncology)

Source-specific interpretation; independent clinician adjudication pending.

Source scope / renal recommendation differences

Siklos - product and source limitations

Verify the age-specific initial dose, tablet strength and hematologic monitoring.

How to use this: Apply only to the stated formulation, indication and renal population.

Siklos - labeled renal guidanceSiklos - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeHydroxyurea scored tablets - SIKLOSSiklos - labeled renal guidanceSiklos - selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76957c0d-0f98-4376-bb06-eee651adc09d

Exact product and population

SIKLOS hydroxyurea 100-mg and 1000-mg scored tablets; sickle cell anemia, age >=2 years

RDM38-SCOPE-hydroxyurea-siklos · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Hydroxyurea scored tablets - SIKLOS

Open original reference

Open / share this exact local source

DailyMed / Medunik USA · SIKLOS hydroxyurea 100-mg and 1000-mg scored tablets; sickle cell anemia, age >=2 years

Renal method: CrCl, mL/min, obtained using a 24-hour urine collection
Source date: November 2023
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

At CrCl >=60 mL/min, the initial daily dose is 20 mg/kg in pediatric patients and 15 mg/kg in adults. Below 60 or in ESRD, reduce by 50%: 10 mg/kg/day in children and 7.5 mg/kg/day in adults. Obtain CrCl using a 24-hour urine collection. On hemodialysis days, administer after dialysis.

For starting-dose weight, use actual or ideal body weight, whichever is less. Monitor blood counts every two weeks and follow the full escalation, toxicity interruption and recovery instructions. These scored tablets are labeled for sickle cell anemia in adults and children at least two years old; do not substitute the adult DROXIA capsule starting dose for the pediatric SIKLOS dose.

RDM38-official-hydroxyurea-siklos-20ae06ae5f-C1 · Source locator: Sections 1, 2.1, 2.2 renal table and 5.1

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76957c0d-0f98-4376-bb06-eee651adc09d
Retrieved
2026-09-07
Exact label title
Hydroxyurea scored tablets - SIKLOS
DailyMed Set ID
76957c0d-0f98-4376-bb06-eee651adc09d
Labeler
Medunik USA
Label revision
November 2023
Renal-function method
CrCl, mL/min, obtained using a 24-hour urine collection
Source date/version
November 2023
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
316f07d515ddc354bd2a13c4156f70103171a19b458af4c48453f08a6a1c0c23
Official

Siklos - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Hydroxyurea (Siklos), oral tablets for sickle cell disease

Renal method: Measured creatinine clearance, mL/min
Source date: DailyMed SPL version 13, posted Jan 08, 2026
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2.2 Dose Modifications for Renal Impairment / 8.6 Renal Impairment

Halve the usual Siklos dose when CrCl is below 60 mL/min or ESRD is present. Give the dose after hemodialysis on treatment days. Verify the age-specific initial dose, tablet strength and hematologic monitoring.

RDM74-siklos-official-1 · Source locator: Renal guidance: 2.2 Dose Modifications for Renal Impairment / 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76957c0d-0f98-4376-bb06-eee651adc09d
Retrieved
2026-11-07
Renal-function method
Measured creatinine clearance, mL/min
Source date/version
DailyMed SPL version 13, posted Jan 08, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
187756b8c731bb4420b1b14f552adb9128564e40881f88f9a284fa1936fbb5b2
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Siklos - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Hydroxyurea (Siklos), oral tablets for sickle cell disease

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

Halve the usual Siklos dose when CrCl is below 60 mL/min or ESRD is present. Give the dose after hemodialysis on treatment days.

RDM74-siklos-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/siklos-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
d073041e383132e19f73684b1f2abf559d7d7f7b160a8b403ffd5de9490f29ad

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76957c0d-0f98-4376-bb06-eee651adc09d
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
source summary
Local text SHA-256
588702d3487b1a354f582210bbbc0297096e5239129e46771cdc64422dd5a6db
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top